Oncimmune (LON:ONC) Hits New 1-Year Low – Here’s What Happened

Oncimmune Holdings plc (LON:ONC)’s stock price hit a new 52-week low during trading on Wednesday . The stock traded as low as GBX 3.86 ($0.05) and last traded at GBX 3.86 ($0.05), with a volume of 541160 shares trading hands. The stock had previously closed at GBX 4 ($0.05).

Oncimmune Price Performance

The company has a market cap of £4.37 million, a PE ratio of 0.44 and a beta of 1.19. The stock has a fifty day moving average price of GBX 12.49 and a 200-day moving average price of GBX 14.65. The company has a debt-to-equity ratio of -412.06, a current ratio of 1.14 and a quick ratio of 0.63.

Oncimmune (LON:ONC) last issued its earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share for the quarter. Oncimmune had a net margin of 581.63% and a negative return on equity of 2,277.74%.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.